ONCOGENEX PHARMACEUTICALS IN's ticker is OGXI and the CUSIP is 68230A106. A total of 68 filers reported holding ONCOGENEX PHARMACEUTICALS IN in Q4 2013. The put-call ratio across all filers is 38.60 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2016 | $195,000 | -51.2% | 396,104 | 0.0% | 0.19% | -55.4% |
| Q2 2016 | $400,000 | +47.6% | 396,104 | 0.0% | 0.42% | +66.3% |
| Q1 2016 | $271,000 | -42.9% | 396,104 | 0.0% | 0.25% | -12.2% |
| Q4 2015 | $475,000 | -64.4% | 396,104 | -34.4% | 0.29% | -63.2% |
| Q3 2015 | $1,334,000 | -5.2% | 603,740 | 0.0% | 0.78% | +21.9% |
| Q2 2015 | $1,407,000 | +10.4% | 603,740 | 0.0% | 0.64% | +17.9% |
| Q1 2015 | $1,274,000 | -5.8% | 603,740 | 0.0% | 0.54% | +41.1% |
| Q4 2014 | $1,352,000 | -15.5% | 603,740 | 0.0% | 0.38% | -59.9% |
| Q3 2014 | $1,600,000 | -28.4% | 603,740 | 0.0% | 0.96% | -7.8% |
| Q2 2014 | $2,234,000 | -68.5% | 603,740 | 0.0% | 1.04% | -73.5% |
| Q1 2014 | $7,088,000 | +40.8% | 603,740 | 0.0% | 3.91% | +3.1% |
| Q4 2013 | $5,035,000 | -10.2% | 603,740 | 0.0% | 3.79% | +18.7% |
| Q3 2013 | $5,609,000 | -5.2% | 603,740 | 0.0% | 3.20% | -29.8% |
| Q2 2013 | $5,917,000 | – | 603,740 | – | 4.55% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Abingworth LLP | 603,740 | $5,917,000 | 4.55% |
| TANG CAPITAL MANAGEMENT LLC | 933,100 | $9,144,000 | 3.60% |
| JAY JEFFREY R | 347,004 | $3,401,000 | 2.69% |
| RA Capital Management | 863,332 | $8,461,000 | 1.12% |
| QVT Financial LP | 400,000 | $3,920,000 | 0.26% |
| SABBY MANAGEMENT, LLC | 396,730 | $3,888,000 | 0.26% |
| J. Goldman & Co LP | 222,907 | $2,184,000 | 0.22% |
| J. Goldman & Co LP | 156,000 | $1,529,000 | 0.16% |
| Tekla Capital Management LLC | 113,100 | $1,108,000 | 0.15% |
| Visium Asset Management, LP | 445,698 | $4,368,000 | 0.10% |